Business
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
~ Moderated Session to Review Latest Data as Recently Presented ~SAN DIEGO, CA / ACCESSWIRE / September 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ Moderated Session to Review Latest Data as Recently Presented ~SAN DIEGO, CA / ACCESSWIRE / September 19, 2023 / Ensysce Biosciences, Inc. (\"Ensysce\" or the \"Company\") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced they will host a Research and Development (\"R&D\") FAQ Session to discuss educational session held at PAINWeek where they presented their approach to delivering the Next Generation of analgesics.The Symposium \"Severe Pain - Next Generation Solutions - PF614/ PF614-MPAR\" featured experts in pain management and prescription drug abuse, Dr. Jeff Gudin from the University of Miami, and Dr. Richard Dart from the Rocky Mountain Poison and Drug Center in Denver, as well as Dr. William Schmidt, Chief Medical Officer of Ensysce who expanded on the recent developments with PF614 and PF614-MPAR. The meeting attracted attention from experts and received extremely positive feedback from attendees.This R&D FAQ Session will provide a summary of the event and discuss the current state of Ensysce's programs being developed for severe pain. Dr. Lynn Kirkpatrick, Ensysce CEO, and Dr. William Schmidt, Ensysce Chief Medical Officer, will discuss the event in moderated format with Geoff Birkett, Ensysce Chief Commercial Officer.R&D FAQ SessionDate: Thursday, September 21, 2023Time: 10:00am ETWebinar: ENSC R&D FAQ SessionPlease pre-submit questions to [email protected] no later than 8:00am ET on Thursday, September 21, 2023.About PF614PF614 is a Trypsin Activated Abuse Protected (TAAPTM) product designed as a delayed onset extended-release oxycodone prodrug. TAAPTM chemical modification inactivates the active ingredient in Ensysce's products including PF614 until they are swallowed. This provides abuse deterrence, resistance to manipulation and other forms of recreational drug abuse, while providing a high degree of pain relief for those who require opioid analgesics for 24/7 round-the-clock severe pain.About Ensysce BiosciencesEnsysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAPä) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is in the process of developing a unique, tamper-proof treatment option for ...